Introduction
The cause of esophageal mucosal breaks in reflux esophagitis is excessive esophageal acid exposure, and the duration of esophageal acid exposure significantly increases with the severity of reflux esophagitis 1 . Esophageal mucosal break can be healed by normalizing (! 4%) excessive esophageal acid exposure. Endoscopic healing can be achieved in 90 100 and 80 85% of patients with mild and severe reflux esophagitis, respectively, by standarddose oral PPI therapy, which is the first-line treatment for GERD 2, 3 . However, according to a report in 2015, the endoscopic healing rate by PPI (primarily standard-dose PPI) therapy decreased to about 70 and 60% in grade C and grade D reflux esophagitis, respectively, based on the LA classification, and the prevalence of severe reflux esophagitis that cannot be healed with standard-dose PPI is increasing 4 . This review gives an overview of treatments for standard-dose PPI-resistant reflux esophagitis.
Treatments for Standard-dose PPI-resistant Reflux Esophagitis

1) Modification of lifestyle
According to the evaluation of acid reflux by the longterm measurement of the esophageal pressure and pH, acid reflux is more often caused by transient LES relaxation than by a low LES pressure 5 8 . Transient LES relaxation is LES relaxation unaccompanied by swallowing, which is the mechanism of belching and is not a morbid reaction 9 ( Fig. 1) . During transient LES relaxation, reflux 2) Reducing the occurrence of acid reflux
Since transient LES relaxation is the primary mechanism of acid reflux, the excessive esophageal acid exposure can be reduced by decreasing the frequency of transient LES relaxation. Baclofen, a GABA-B agonist, is a drug clinically available for reducing the frequency of transient LES relaxation 13 15 . However, considering that the use of baclofen for the treatment of reflux esophagitis is off-label use for the purpose of coverage by the national health insurance scheme, that it has been reportedly used at higher doses abroad than in Japan, and that it has central nervous system side effects, suppression of the frequency of transient LES relaxation with baclofen is not practical.
While there is no difference in the frequency of transient LES relaxation between healthy subjects and GERD patients 5 8 (Table 1) , the frequency of acid reflux during transient LES relaxation is significantly greater in GERD patients than in healthy subjects 5 8 (Table 2) . Therefore, the cause of excessive esophageal acid exposure in patients with reflux esophagitis is not the high frequency of transient LES relaxation but the higher rate of acid reflux during transient LES relaxation.
With regard to the difference in proportion of acid reflux during TLESR, it is considered that the location of the acid pocket, which is the layer of acid that appears postprandially above the dietary layer immediately below the esophagogastric junction (EGJ) as a source of postprandial acid reflux is very important 16 18 . When the acid pocket is located in the hernia sac (supradiaphragmatic location), the proportion of acid reflux episodes 3) Improving the esophageal acid clearance
In patients who show delayed esophageal acid clearance, the duration of excessive esophageal acid exposure can be reduced by improving the esophageal acid clearance. According to our evaluation, there was no clear difference in primary peristalsis, which is important for esophageal acid clearance, between in patients with mild reflux esophagitis and healthy subjects 7, 19 , but mild abnormalities of peristaltic activity may be observed in individual patients. In such patients, peristaltic activity may be improved by the administration of gastrointestinal prokinetic drugs 20 . On the other hand, the esophageal acid clearance is markedly delayed in patients with severe reflux esophagitis, but the effect of the administration of gastrointestinal prokinetic drugs is limited.
4) Acid control
Although excessive esophageal acid exposure is the cause of reflux esophagitis for acid secretion, such as a meal, and acid is secreted from the proton pumps that appear on the membranes of secretory canaliculi. PPI are activated by acid in the secretory canaliculi, and acid secretion is suppressed as activated PPI bind covalently with proton pumps on the membranes of secretory canaliculi. To maximize the effect of a PPI, it is necessary to set its peak circulating concentration after a meal. Since the blood concentration of PPI reaches a peak 2 3 hours after oral administration, it is considered effective to administer PPI 1 hour before a meal 22 . In addition, it is effective to administer PPI before dinner 23 , because the largest number of proton pumps appear on the membranes of secretory canaliculi after dinner, which is generally the most substantial meal of the day.
4-3) Changing the dose of PPI
Even when endoscopic healing cannot be achieved with a standard dose of PPI, reflux esophagitis, which is caused by excessive esophageal acid exposure, is healed by more potent suppression of acid secretion with double dose PPI. In double-dose PPI therapy, it is more effective to administer in divided doses rather than in a single dose 24 . Splitting the dose and, thus, creating a bimodal distribution of the plasma PPI concentration is more advantageous, (1) because PPI in the secretory canaliculi activated by gastric acid are rapidly deactivated and acid secretion from proton pumps on the membranes of secretory canaliculi which appear after the plasma PPI concentration disappears about 10 12 hours after administration of PPI is not suppressed, and (2) because about 25% of the proton pumps are newly produced daily 25 .
4-4) Switching to vonoprazan
In February 2015, vonoprazan, which is a novel acid secretion-inhibitory drug, became available. While vonoprazan targets proton pumps similarly to PPI, it competitively inhibits the binding of the proton pump to potassium ions and belongs to a new category (potassiumcompetitive acid blocker) different from PPI. Characteristics of vonoprazan are the rapid onset, high potency, and long duration of its acid secretion-inhibitory effect 25, 26 . Excellent results have also been reported by its clinical trials against reflux esophagitis 28, 29 . However, there is also concern over adverse effects associated with its strong acid-suppressive effect. There are no other conflicts of interest to declare.
